Q1 EPS Estimate for Simulations Plus Decreased by Analyst

Simulations Plus, Inc. (NASDAQ:SLP) – Equities researchers at William Blair decreased their Q1 2026 EPS estimates for Simulations Plus in a report released on Monday, January 27th. William Blair analyst M. Smock now anticipates that the technology company will post earnings of $0.16 per share for the quarter, down from their prior estimate of $0.17. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share. William Blair also issued estimates for Simulations Plus’ Q2 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.41 EPS and FY2026 earnings at $1.32 EPS.

Several other equities research analysts have also recently weighed in on the stock. Stephens began coverage on shares of Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. KeyCorp upped their target price on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, BTIG Research reduced their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Stock Down 0.6 %

Shares of NASDAQ:SLP opened at $33.80 on Wednesday. Simulations Plus has a 52-week low of $24.00 and a 52-week high of $51.22. The business’s 50 day moving average is $30.19 and its 200 day moving average is $32.70. The stock has a market cap of $679.04 million, a P/E ratio of 84.50 and a beta of 0.80.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. First Horizon Advisors Inc. boosted its holdings in Simulations Plus by 82.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after purchasing an additional 370 shares during the last quarter. nVerses Capital LLC raised its position in shares of Simulations Plus by 1,100.0% during the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after buying an additional 1,100 shares during the period. Quantbot Technologies LP acquired a new position in Simulations Plus in the third quarter valued at approximately $59,000. US Bancorp DE grew its position in Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after acquiring an additional 1,343 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Simulations Plus by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock worth $311,000 after acquiring an additional 456 shares during the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $31.76, for a total transaction of $635,200.00. Following the transaction, the director now directly owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 19.40% of the stock is currently owned by company insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.